Condition (MeSH)
Immunoblastic Lymphadenopathy
ClinicalTrials.gov lists 272 trials for Immunoblastic Lymphadenopathy or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 43.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
272 of the 272 trials are tagged with Immunoblastic Lymphadenopathy itself; the rest are tagged with a narrower condition beneath it.
When did Immunoblastic Lymphadenopathy trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 20
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 8 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 5 |
| 2017 | 7 |
Showing 10 of 34 earlier years.
No forecast is made for this condition: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 214 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Immunoblastic Lymphadenopathy trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 112 |
| Phase 1/2 | 30 |
| Phase 2 | 61 |
| Phase 2/3 | 1 |
| Phase 3 | 23 |
| Phase 4 | 2 |
| Not applicable | 24 |
| Observational | 18 |
| Unknown | 1 |
How many Immunoblastic Lymphadenopathy trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 11 |
| Active, not recruiting | 9 |
| Completed | 173 |
| Suspended | 4 |
| Terminated | 36 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Immunoblastic Lymphadenopathy trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 43 |
| European Organisation for Research and Treatment of Cancer - EORTC | 6 |
| National Institutes of Health Clinical Center (CC) | 6 |
Which drugs are being tested for Immunoblastic Lymphadenopathy? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 36 |
| Prednisone | 14 |
| Busulfan | 12 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 29 |
| Peripheral blood stem cell transplantation | 25 |
| Total Body Irradiation | 18 |
| Cyclosporine 0.05% | 17 |
| Etoposid | 17 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Immunoblastic Lymphadenopathy trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| 1 yr TRM | 93 | 1 |
| Platelet count decreased | 91 | 12 |
| Febrile neutropenia | 73 | 17 |
| Neutrophil count decreased | 55 | 16 |
| Fever | 42 | 15 |
Showing 5 of 10 adverse events.
Which publications cover Immunoblastic Lymphadenopathy? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma. | Clinical lymphoma, myeloma & leukemia | 2022 | Yes |
| Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. | Blood | 2021 | Yes |
| Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. | Blood | 2002 | Yes |
| The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. | Cancer | 2019 | No |
| How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. | British journal of haematology | 2017 | No |
Showing 5 of 7 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Angioimmunoblastic T-cell lymphoma | Annual incidence | <1 / 1 000 000 | United States | US | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.